Table 3.
Liver parameters of the enrolled subjects at the baseline and during treatment
| Phytosomal curcumin (N. 40) | Placebo (N. 40) | |||||
|---|---|---|---|---|---|---|
| T0 | T1 (28 days) | T2 (56 days) | T0 | T1 (28 days) | T2 (56 days) | |
| GOT (U/L) | 21 ± 6 | 18 ± 3 | 16 ± 5*° | 23 ± 5 | 21 ± 7 | 21 ± 8 |
| GPT (U/L) | 23 ± 7 | 21 ± 3 | 15 ± 3*° | 24 ± 7 | 22 ± 6 | 21 ± 9 |
| gGT (U/L) | 28 ± 9 | 25 ± 7 | 24 ± 6* | 27 ± 9 | 26 ± 9 | 26 ± 7 |
| LAP | 64 ± 14 | 63 ± 12 | 62 ± 10* | 65 ± 13 | 64 ± 12 | 64 ± 13 |
| HSI | 38 ± 5 | 36 ± 5 | 35 ± 4* | 39 ± 6 | 38 ± 5 | 37 ± 4 |
| FLI | 57 ± 11 | 55 ± 9 | 54 ± 9*° | 58 ± 10 | 57 ± 9 | 57 ± 10 |
GOT glutamic oxaloacetic transaminase, GPT glutamate pyruvate transaminase, gGT gamma-glutamyl transferase, LAP lipid accumulation product, HSI hepatic steatosis index, FLI fatty liver index
*p < 0.05 vs. baseline; °p < 0.05 vs. placebo